Motif Bio PLC (LON:MTFB) had its Under Review rating reiterated by Peel Hunt

Analyst Ratings For Motif Bio PLC (LON:MTFB)

Story continues below

Today, Peel Hunt reiterated its Under Review rating on Motif Bio PLC (LON:MTFB).

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Motif Bio PLC (LON:MTFB) is Buy with a consensus target price of GBX 105.50 per share, a potential .

Some recent analyst ratings include

  • 2/14/2019-Motif Bio PLC (LON:MTFB) had its Under Review rating reiterated by Peel Hunt
  • 10/31/2018-Motif Bio PLC (LON:MTFB) had its Buy rating reiterated by Northland Securities
  • 11/22/2017-Motif Bio PLC (LON:MTFB) had its Buy rating reiterated by FinnCap with a GBX 100 price target
  • 11/16/2017-Motif Bio PLC (LON:MTFB) had its Speculative Buy rating reiterated by Beaufort Securities with a GBX 110 price target

    About Motif Bio PLC (LON:MTFB)
    Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

    Recent Trading Activity for Motif Bio PLC (LON:MTFB)
    Shares of Motif Bio PLC closed the previous trading session at 5.85 −34.15 85.38% with 10.7 shares trading hands.

    An ad to help with our costs